| Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer L Gandhi, D Rodríguez-Abreu, S Gadgeel, E Esteban, E Felip, ... New England journal of medicine 378 (22), 2078-2092, 2018 | 6213 | 2018 |
| Updated analysis from KEYNOTE-189: pembrolizumab or placebo plus pemetrexed and platinum for previously untreated metastatic nonsquamous non–small-cell lung cancer S Gadgeel, D Rodríguez-Abreu, G Speranza, E Esteban, E Felip, ... Journal of clinical oncology 38 (14), 1505-1517, 2020 | 1028 | 2020 |
| First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial P Baas, A Scherpereel, AK Nowak, N Fujimoto, S Peters, AS Tsao, ... The Lancet 397 (10272), 375-386, 2021 | 962 | 2021 |
| COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study MC Garassino, JG Whisenant, LC Huang, A Trama, V Torri, F Agustoni, ... The Lancet Oncology 21 (7), 914-922, 2020 | 680 | 2020 |
| Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non–small-cell lung cancer G Scagliotti, S Novello, J von Pawel, M Reck, JR Pereira, M Thomas, ... Journal of Clinical Oncology 28 (11), 1835-1842, 2010 | 514 | 2010 |
| Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma GL Ceresoli, PA Zucali, AG Favaretto, F Grossi, P Bidoli, G Del Conte, ... Journal of clinical oncology 24 (9), 1443-1448, 2006 | 379 | 2006 |
| Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional … B Ricciuti, C Genova, A De Giglio, M Bassanelli, MG Dal Bello, G Metro, ... Journal of cancer research and clinical oncology 145, 479-485, 2019 | 323 | 2019 |
| Pembrolizumab plus pemetrexed and platinum in nonsquamous non–small-cell lung cancer: 5-year outcomes from the phase 3 KEYNOTE-189 study MC Garassino, S Gadgeel, G Speranza, E Felip, E Esteban, M Dómine, ... Journal of Clinical Oncology 41 (11), 1992-1998, 2023 | 278 | 2023 |
| IL‐8 induces exocytosis of arginase 1 by neutrophil polymorphonuclears in nonsmall cell lung cancer R Rotondo, G Barisione, L Mastracci, F Grossi, AM Orengo, R Costa, ... International journal of cancer 125 (4), 887-893, 2009 | 249 | 2009 |
| Association of steroids use with survival in patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis F Petrelli, D Signorelli, M Ghidini, A Ghidini, EG Pizzutilo, L Ruggieri, ... Cancers 12 (3), 546, 2020 | 248 | 2020 |
| PD/1-PD-Ls checkpoint: insight on the potential role of NK cells S Pesce, M Greppi, F Grossi, G Del Zotto, L Moretta, S Sivori, C Genova, ... Frontiers in immunology 10, 1242, 2019 | 193 | 2019 |
| Decline in serum carcinoembryonic antigen and cytokeratin 19 fragment during chemotherapy predicts objective response and survival in patients with advanced nonsmall cell lung … A Ardizzoni, MA Cafferata, M Tiseo, R Filiberti, P Marroni, F Grossi, ... Cancer 107 (12), 2842-2849, 2006 | 193 | 2006 |
| Predictive value of a proteomic signature in patients with non-small-cell lung cancer treated with second-line erlotinib or chemotherapy (PROSE): a biomarker-stratified … V Gregorc, S Novello, C Lazzari, S Barni, M Aieta, M Mencoboni, F Grossi, ... The lancet oncology 15 (7), 713-721, 2014 | 187 | 2014 |
| Crizotinib in MET-Deregulated or ROS1-Rearranged Pretreated Non–Small Cell Lung Cancer (METROS): A Phase II, Prospective, Multicenter, Two-Arms Trial L Landi, R Chiari, M Tiseo, F D'Incà, C Dazzi, A Chella, A Delmonte, ... Clinical cancer research 25 (24), 7312-7319, 2019 | 176 | 2019 |
| The role of CEA, CYFRA21-1 and NSE in monitoring tumor response to Nivolumab in advanced non-small cell lung cancer (NSCLC) patients MG Dal Bello, RA Filiberti, A Alama, AM Orengo, M Mussap, S Coco, ... Journal of Translational Medicine 17, 1-10, 2019 | 176 | 2019 |
| Italian, multicenter, phase III, randomized study of cisplatin plus etoposide with or without bevacizumab as first-line treatment in extensive-disease small-cell lung cancer … M Tiseo, L Boni, F Ambrosio, A Camerini, E Baldini, S Cinieri, M Brighenti, ... Journal of Clinical Oncology 35 (12), 1281-1287, 2017 | 171 | 2017 |
| Pleural and peripheral lung lesions: comparison of US-and CT-guided biopsy LM Sconfienza, G Mauri, F Grossi, M Truini, G Serafini, F Sardanelli, ... Radiology 266 (3), 930-935, 2013 | 167 | 2013 |
| Afatinib beyond progression in patients with non-small-cell lung cancer following chemotherapy, erlotinib/gefitinib and afatinib: phase III randomized LUX-Lung 5 trial M Schuler, JCH Yang, K Park, JH Kim, J Bennouna, YM Chen, C Chouaid, ... Annals of Oncology 27 (3), 417-423, 2016 | 166 | 2016 |
| Safety and efficacy of buparlisib (BKM120) in patients with PI3K pathway-activated non-small cell lung cancer: results from the phase II BASALT-1 study JF Vansteenkiste, JL Canon, F De Braud, F Grossi, T De Pas, JE Gray, ... Journal of Thoracic Oncology 10 (9), 1319-1327, 2015 | 163 | 2015 |
| Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer S Salvi, V Fontana, S Boccardo, DF Merlo, E Margallo, S Laurent, ... Cancer Immunology, Immunotherapy 61, 1463-1472, 2012 | 162 | 2012 |
